SynthesisJournal of cosmetic dermatology2025
Efficacy and Safety of Combined Platelet-Rich Plasma With Fractional Laser for Adult Patients With Vitiligo: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Synthesis in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Comment on "Efficacy and Safety of Combined Platelet-Rich Plasma With Fractional Laser for Adult Patients With Vitiligo: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".Journal of cosmetic dermatology · 2026Article
- Ultraviolet radiation as a double-edged regulator of melanocyte function in vitiligo therapy and melanoma carcinogenesis.Frontiers in medicine · 2026Review
- Platelet-rich therapies in cutaneous and mucocutaneous disorders characterized by inflammatory tissue responses: mechanistic insights and clinical evidence.Frontiers in medicine · 2026Review
- Anticoagulant-free preparation of autologous platelet-rich plasma (PRP) / fluid platelet-rich fibrin (f-PRF): a pre-clinical comparative performance study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivePlatelet-rich plasma (PRP) is a novel treatment option for vitiligo. It has been reported to be effective in combination with other methods, such as fractional laser. However, there is no consensus on the specific combined use of PRP with fractional laser. Therefore, this meta-analysis assessed the efficacy and safety of this combination regimen compared to control groups for vitiligo.
methodsA comprehensive literature search was conducted for relevant randomized controlled trials comparing PRP plus fractional laser with other routine treatments published from inception to January 2025. Data regarding the mean grade of repigmentation, patient's satisfaction score, rate of satisfactory repigmentation or no response, and incidence of side effects were extracted and meta-analyzed using a fixed or randomized model.
resultsSeven studies involving 366 patients were reviewed. The combination of PRP and fractional laser therapy significantly improved the mean grade of repigmentation (mean difference [MD] = 1.58; 95% confidence interval [CI] = 1.08-2.07; p < 0.01) and patients' satisfaction score (MD = 1.87; 95% CI = 0.90-2.83; p = 0.0001), while also reducing the no response rate (risk ratio [RR] = 0.54; 95% CI = 0.32-0.92; p = 0.02), compared with control groups, including monotherapy, topical drug or sun exposure only, and fractional lasers plus narrowband ultraviolet B. Additionally, the incidence of adverse events for combination therapy was comparable to that of control groups (RR = 0.86; 95% CI = 0.69-1.07; p = 0.17).
conclusionsThis meta-analysis provides evidence supporting the combined use of PRP and fractional laser therapy as a valuable and safe treatment modality for patients with vitiligo, based on its superiority to control groups and comparable rates of side effects. However, more well-designed and large-scale studies are required to confirm it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.